Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
{{output}}
Objective: PATENT-1 and CHEST-1 were pivotal, international phase III trials assessing riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Here we compare Chinese patient... ...
